133 related articles for article (PubMed ID: 31002563)
1. Simulating Time-Dependent Patterns of Nonadherence by Patients With Breast Cancer to Adjuvant Oral Endocrine Therapy.
Shinn EH; Broderick G; Fellman B; Johnson A; Wieland E; Moulder S; Symmans WF
JCO Clin Cancer Inform; 2019 Apr; 3():1-9. PubMed ID: 31002563
[TBL] [Abstract][Full Text] [Related]
2. Patterns of endocrine therapy in a national cohort of early stage HER2-positive breast cancer patients.
Tervonen HE; Daniels B; Tang M; Preen DB; Pearson SA
Pharmacoepidemiol Drug Saf; 2019 Jun; 28(6):812-820. PubMed ID: 30861596
[TBL] [Abstract][Full Text] [Related]
3. Persistence and discontinuation of adjuvant endocrine therapy in women with breast cancer.
Kuba S; Ishida M; Nakamura Y; Taguchi K; Ohno S
Breast Cancer; 2016 Jan; 23(1):128-133. PubMed ID: 24934610
[TBL] [Abstract][Full Text] [Related]
4. Analysis of Adjuvant Endocrine Therapy in Practice From Electronic Health Record Data of Patients With Breast Cancer.
Harrell M; Fabbri D; Levy M
JCO Clin Cancer Inform; 2017 Nov; 1():1-8. PubMed ID: 30657375
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant aromatase inhibitor therapy in early breast cancer: what factors lead patients to discontinue treatment?
Moscetti L; Agnese Fabbri M; Sperduti I; Fabrizio N; Frittelli P; Massari A; Pompei L; D'Auria G; Pofi E; Ruggeri EM
Tumori; 2015; 101(5):469-73. PubMed ID: 26108239
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant endocrine therapy for breast cancer patients: impact of a health system outreach program to improve adherence.
Lee C; Check DK; Manace Brenman L; Kushi LH; Epstein MM; Neslund-Dudas C; Pawloski PA; Achacoso N; Laurent C; Fehrenbacher L; Habel LA
Breast Cancer Res Treat; 2020 Feb; 180(1):219-226. PubMed ID: 31975315
[TBL] [Abstract][Full Text] [Related]
7. Five-Year Adjuvant Endocrine Therapy Adherence Trajectories Among Women With Breast Cancer: A Nationwide French Study Using Administrative Data.
Lailler G; Memoli V; Le Bihan Benjamin C; Ben Diane MK; Lauzier S; Mancini J; Bousquet PJ; Bouhnik AD
Clin Breast Cancer; 2021 Aug; 21(4):e415-e426. PubMed ID: 33745868
[TBL] [Abstract][Full Text] [Related]
8. Clinical consultations and investigations before and after discontinuation of endocrine therapy in women with primary breast cancer.
Lopez D; Kemp-Casey A; Saunders C; Roughead E; Boyle F; Bulsara M; Preen D
Public Health Res Pract; 2017 Jul; 27(3):. PubMed ID: 28765859
[TBL] [Abstract][Full Text] [Related]
9. Adherence to Adjuvant Endocrine Therapy in Women With Breast Cancer: A Prospective Observational Study in Japanese Women.
Kuba S; Maeda S; Matsumoto M; Yamanouchi K; Yano H; Morita M; Sakimura C; Hatachi T; Tokai Y; Takatsuki M; Fujioka H; Hayashida N; Nagayasu T; Eguchi S
Clin Breast Cancer; 2018 Apr; 18(2):150-156. PubMed ID: 29290564
[TBL] [Abstract][Full Text] [Related]
10. Adherence to adjuvant endocrine therapy in women with breast cancer.
Danilak M; Chambers CR
J Oncol Pharm Pract; 2013 Jun; 19(2):105-10. PubMed ID: 22895656
[TBL] [Abstract][Full Text] [Related]
11. High non-compliance in the use of letrozole after 2.5 years of extended adjuvant endocrine therapy. Results from the IDEAL randomized trial.
Fontein DB; Nortier JW; Liefers GJ; Putter H; Meershoek-Klein Kranenbarg E; van den Bosch J; Maartense E; Rutgers EJ; van de Velde CJ
Eur J Surg Oncol; 2012 Feb; 38(2):110-7. PubMed ID: 22172646
[TBL] [Abstract][Full Text] [Related]
12. Adherence to adjuvant endocrine therapy in postmenopausal breast cancer patients: A 5-year prospective study.
Hagen KB; Aas T; Kvaløy JT; Søiland H; Lind R
Breast; 2019 Apr; 44():52-58. PubMed ID: 30641300
[TBL] [Abstract][Full Text] [Related]
13. Endocrine Therapy Nonadherence and Discontinuation in Black and White Women.
Wheeler SB; Spencer J; Pinheiro LC; Murphy CC; Earp JA; Carey L; Olshan A; Tse CK; Bell ME; Weinberger M; Reeder-Hayes KE
J Natl Cancer Inst; 2019 May; 111(5):498-508. PubMed ID: 30239824
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant endocrine therapy uptake, toxicity, quality of life, and prediction of early discontinuation.
Balazard F; Bertaut A; Bordet É; Mulard S; Blanc J; Briot N; Paux G; Dhaini Merimeche A; Rigal O; Coutant C; Fournier M; Jouannaud C; Soulie P; Lerebours F; Cottu PH; Tredan O; Vanlemmens L; Levy C; Mouret-Reynier MA; Campone M; Brady KJS; Sasane M; Rice M; Coulouvrat C; Martin AL; Jacquet A; Vaz-Luis I; Herold C; Pistilli B
J Natl Cancer Inst; 2023 Sep; 115(9):1099-1108. PubMed ID: 37434306
[TBL] [Abstract][Full Text] [Related]
15. Nonadherent behaviors among young women on adjuvant endocrine therapy for breast cancer.
Wassermann J; Gelber SI; Rosenberg SM; Ruddy KJ; Tamimi RM; Schapira L; Borges VF; Come SE; Meyer ME; Partridge AH
Cancer; 2019 Sep; 125(18):3266-3274. PubMed ID: 31120571
[TBL] [Abstract][Full Text] [Related]
16. Good adherence to adjuvant endocrine therapy in early breast cancer - a population-based study based on the Swedish Prescribed Drug Register.
Lundgren C; Lindman H; Rolander B; Ekholm M
Acta Oncol; 2018 Jul; 57(7):935-940. PubMed ID: 29493327
[TBL] [Abstract][Full Text] [Related]
17. Geographic disparities in adherence to adjuvant endocrine therapy in Appalachian women with breast cancer.
Tan X; Camacho F; Marshall VD; Donohoe J; Anderson RT; Balkrishnan R
Res Social Adm Pharm; 2017; 13(4):796-810. PubMed ID: 27641308
[TBL] [Abstract][Full Text] [Related]
18. Cognitive function and discontinuation of adjuvant hormonal therapy in older breast cancer survivors: CALGB 369901 (Alliance).
Bluethmann SM; Alfano CM; Clapp JD; Luta G; Small BJ; Hurria A; Cohen HJ; Sugarman S; B Muss H; Isaacs C; Mandelblatt JS
Breast Cancer Res Treat; 2017 Oct; 165(3):677-686. PubMed ID: 28653250
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer patients' insurance status and residence zip code correlate with early discontinuation of endocrine therapy: An analysis of the ECOG-ACRIN TAILORx trial.
Sadigh G; Gray RJ; Sparano JA; Yanez B; Garcia SF; Timsina LR; Sledge GW; Cella D; Wagner LI; Carlos RC
Cancer; 2021 Jul; 127(14):2545-2552. PubMed ID: 33793979
[TBL] [Abstract][Full Text] [Related]
20. Treatment decisions and the impact of adverse events before and during extended endocrine therapy in postmenopausal early breast cancer.
Blok EJ; Kroep JR; Meershoek-Klein Kranenbarg E; Duijm-de Carpentier M; Putter H; Liefers GJ; Nortier JWR; Rutgers EJT; Seynaeve CM; van de Velde CJH;
Eur J Cancer; 2018 May; 95():59-67. PubMed ID: 29635145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
